

European Cycle on Innovation
Paris, May 31st 2005

EU 6th Framework Programme
SME participation in the 4th and last calls of :

TP1 - « Life sciences, genomics and biotechnology for health »
&
TP5 - « Food quality and Safety »

Workshop 1 :
Life sciences European partnering event

Catalogue of Partner-searches and SME competencies

This Catalogue presents the project ideas and partner searches that have been gathered in the frame of the event held in Paris on the 31st of May.

Some of them have been presented during the specific workshop 1, their powerpoint presentations are available at the following link : <http://www.eurosfairerprd.fr/ji/index-ji310505p-en.html>

Some partner searches did not get the opportunity to be presented during the session but are looking for partners to build European projects.

For Thematic Priority 1, « Life sciences, genomics and biotechnology for health », 13 partner searches are presented in this catalogue : the summary is presented on page 3.

For Thematic Priority 5, « Food Quality and Safety », 6 partner searches are presented in this catalogue : the summary is presented on page 33.

Thematic Priority 1

**« Life sciences, genomics and
biotechnology for health »**

CLASSIFICATION OF PROJECT IDEAS AND SME COMPETENCIES

- i) **Advanced genomics and its application for health**
- a) **Fundamental knowledge and basic tools for functional genomics in all organisms**
- Gene expression and proteomics
 Covalys Biosciences – IP (presented in the session)..... p.20
 - Structural genomics
 Covalys Biosciences – IP (presented in the session)..... p.20
 Plirosoft GmbH - (presented in the session)..... p.29
 - Comparative genomics and population genetic
 Plirosoft GmbH - (presented in the session)..... p.29
 - Bioinformatics
 - Multidisciplinary functional genomics approaches to basic biological processes
 Covalys Biosciences – IP (presented in the session)..... p.20
- b) **Application of knowledge and technologies in the field of genomics and biotechnology for health**
- Rational and accelerated development of new, safer, more effective drugs including pharmacogenomics approaches
 Skuld-Tech – SME STREP p.5
 CeeD – STREP (presented in the session)..... p.13
 ADDEX Pharmaceuticals SA (presented in the session)..... p.23
 TheraStrat AG (presented in the session)..... p.31
 - Development of new diagnostics
 Skuld-Tech – SME STREP p.5
 Covalys Biosciences – IP (presented in the session)..... p.20
 InPheno AG - (presented in the session)..... p.25
 FHBB- Myovec – IP (presented in the session)..... p.27
 - Development of new in vitro tests to replace animal experimentation
 Cell Tissue Progress – SME STREP p.7
 WATCHFROG – SME STREP p.15
 - Development and testing of new preventive and therapeutic tools, such as somatic gene and cell therapies (in particular stem cell therapies, f.e. those on neurological and neuromuscular disorders) and immunotherapies
 - Innovative research in post-genomics which has high potential for application
 Skuld-Tech – SME STREP p.5

ii) **Combating major diseases**

a) **Applications-orientated genomic approaches to medical knowledge and technologies**

- Combating cardiovascular disease, diabetes and rare diseases
 - Mellitech – STREP**..... p. 9
 - Mellitech – SME STREP**..... p.9
 - Cell Tissue Progress – SME STREP** p.7
 - Institut de Biologie Structurale** p.17
- Combating resistance to antibiotics and other drugs
 - InPheno AG - (presented in the session)**..... p.25
- Studying the brain and combating diseases of the nervous system
 - INSERM – SME STREP (presented in the session)**..... p.11
 - Cell Tissue Progress – SME STREP** p.7
 - WATCHFROG – SME STREP** p.15
 - Covalys Biosciences – IP (presented in the session)**..... p.20
 - ADDEX Pharmaceuticals SA (presented in the session)**..... p.23
- Studying human development and the ageing process
 - Cell Tissue Progress – SME STREP** p.7

b) **Combating cancer**

- Skuld-Tech – SME STREP** p.5
- InPheno AG - (presented in the session)**..... p.25

c) **Confronting the major communicable diseases linked to poverty**

- Developing new promising candidate vaccines and therapies
 - InPheno AG - (presented in the session)**..... p.25
 - Plirosoft GmbH - (presented in the session)**..... p.29
- Establishing a programme for advanced clinical trials

CONTACT

Organisation	Skuld-Tech	Department	
Contact person	Didier Ritter	Male/female	
Address	88, cour des Camisards	Email	info@skuldtech.com
Postcode	34080	Fax	0467526396
City	Montpellier	Website	http://www.skuldtech.com
Country	France		

Are you familiar with the European Framework Programme? YES NO

PROJECT idea

Title		Acronym	
Project type	<input type="checkbox"/> Integrated Project	<input type="checkbox"/> Network of Excellence	<input type="checkbox"/> STREP
Status	<input type="checkbox"/> planned for submission	<input type="checkbox"/> running EU project	<input type="checkbox"/> Other:
Call references			

4th Call / Specific STREP dedicated to SMEs call : topics targeted

- Rational and accelerated development of new, safer, more effective drugs including pharmacogenomics approaches
- Development of new diagnostics
- Innovative research in post-genomics, which has high potential for application
- Innovative technological approaches for cancer therapy

Project description

Project description	The principal objective of this research is to identify a palette of gene expression changes associated with the biologic disturbances unique to doping. These changes could be used to detect and thereby deter athletes from using any of the plethora of agents capable for instance of increasing the oxygen carrying capacity of their blood. The goal is to provide antidoping authorities with a single test capable of detecting use of any of the spectrum of agents. Moreover this strategy and the enhanced understanding of gene expression changes offers promise as a platform for investigating the potential for such markers to detect gene doping.
Keywords	Diagnosis, antidoping, doping, blood, gene expression,
Partners already involved	SIAB Pr. Michel Audran (Université Montpellier I) Pr Jacques Marti (Université Montpellier II)

Profile of SME / partner sought

Role	<input type="checkbox"/> technology development	<input type="checkbox"/> research	<input type="checkbox"/> training
	<input type="checkbox"/> dissemination	<input type="checkbox"/> demonstration	<input type="checkbox"/> other _____
Country /region			
Start of partnership	<input type="checkbox"/> start-up phase	<input type="checkbox"/> mid-term	<input type="checkbox"/> end-phase
	Expertise required		

CONTACT

Organisation	Cell Tissue Progress	Department	
Contact person	Christopher CONWAY	Male/female	Male
Address	40 rue Damrémont	Email	c.conway@celltissprog.com
Postcode	75018	Fax	+33 6 6261 19 91
City	Paris	Website	www.celltissprog.com
Country	France		

Are you familiar with the European Framework Programme? YES NO

PROJECT

Title : Standardized cell culture system for stem cells	Acronym
--	----------------

Project type	<input type="checkbox"/> Integrated Project	<input type="checkbox"/> Network of Excellence	<input type="checkbox"/> STREP	<input type="checkbox"/> Other:
Status	<input type="checkbox"/> planned for submission <input type="checkbox"/> running EU project			
Call references				

4th Call / Specific STREP dedicated to SMEs call : topics targeted

- Development of new *in vitro* tests to replace animal experimentation
- Development and testing of new preventive and therapeutic tools, such as somatic gene and cell therapies (in particular stem cell therapies, for example those on neurological and neuromuscular disorders) and immunotherapies
- Research on cardiovascular disease with strong SME involvement
- Development of *in vitro* and/or animal models for rare diseases
- Neuroscience-oriented new technologies
- Early markers and new targets for neurodegenerative diseases

Project description

Project description Cell Tissue Progress (CTP) has developed an *in vitro* cell culture system offering the optimal culture environment for cell experiments. The system called CTP Tide System allows to grow and study cells under controlled dynamic conditions in a total safe and autonomous environment.

The CTP Tide System is devoted to research activities which need better understanding of biological behaviour in intact primary cells and evaluating of molecular interaction with the context of cellular environment.

The CTP technology can play a role in the future development of functional cell based assays and cell therapy by mastering stem cell culture.

The project is the setting up of our cell culture technology adapted to the culture and study of stem cells.

The technology developed consists in an equipment which supplies all culture conditions in continuous controlled by a dedicated software. A sterile disposable culture module recreate the micro-environment where cells grow and investigators carry out experiments directly on living cells.

	<p>The set up of specific culture parameters guarantees an homogeneous and continuous cell culture micro-environment for long term study of the biological activity :</p> <ul style="list-style-type: none"> - temperature is continuously maintained - suitable aeration conditions are delivered to culture medium - medium renewal contribute to maintain biological activity <p>The user can thus develop more complete and better mastered experimental studies by carrying out all kinds of cell culture operations (seeding, culture, sampling, injections, observations under microscope) with a minimum amount of movement and disturbance of the culture.</p> <p>Cultures carried out in this way come close to physiological conditions and enable research departments to analyse cellular mechanisms and interactions with drug very closely, in a perfectly repeatable and controlled manner.</p> <p>The CTP Tide System is characterized by its high degree of reproducibility and traceability under conditions offering an integrated and complete cell culture process.</p>
Keywords	<p>Primary and normal cell culture, Alternative to animal experiment, Adult and embryonic stem cell, Long term culture, Co-culture, living cell observation (time-lapse).</p> <p>Target identification, preclinical validation, toxicology, pharmacology</p>
Partners already involved	

Profile of SME / partner sought

Role	<input checked="" type="checkbox"/> technology development	<input checked="" type="checkbox"/> research	<input type="checkbox"/> training
	<input type="checkbox"/> dissemination	<input checked="" type="checkbox"/> demonstration	<input type="checkbox"/> other _____
Country /region	Germany – UK – Belgium		
Start of partnership	<input type="checkbox"/> start-up phase	<input type="checkbox"/> mid-term	<input type="checkbox"/> end-phase
Expertise required	<p>1. For Drug discovery : Pharmaceutical, Biotech and Academic research centers New target identification, Drug targetting, efficacy assays, and drug validation as research activities.</p> <p>2. For Products-Reagents development (serum free culture media, cell markers, growth factors, biomaterials) : Pharmaceutical, Biotech and Academic research centers Targetting, efficacy assays, product development, process optimisation, product validation as research activities.</p>		

CONTACT

Organisation	Mellitech	Department	
Contact person	Yann de Boysson	Male/female	Male
Address	9a chemin des prés	Email	y.deboysson@mellitech.com
Postcode	38240	Fax	04 76 61 92 92
City	Meylan	Website	www.mellitech.com
Country	France		

Are you familiar with the European Framework Programme? YES NO

PROJECT idea 1

Molecular pathways underlying decreased beta cell mass in diabetes mellitus	Combating diabetes
Project type	<input type="checkbox"/> Integrated Project <input type="checkbox"/> Network of Excellence <input checked="" type="checkbox"/> STREP <input type="checkbox"/> Other: _____
Status	<input checked="" type="checkbox"/> planned for submission <input type="checkbox"/> running EU project
Call references	Call 4 / combating major diseases / Applications-orientated genomic approaches to medical knowledge and technologies / LSH-2005-2.1.1-6
Topic (according to the workprogramme)	LSH-2005-2.1.1-6 : Molecular pathways underlying decreased beta cell mass in diabetes mellitus

Project description

Project description	<p>Mellitech is a SME dedicated to developing :</p> <ul style="list-style-type: none"> - new drugs for the treatment of type II diabetes - bio-tools to enhance diabetes research, through better beta cell comprehension and manipulation (monoclonal antibody) and an animal model for type I <p>Mellitech is conducting R&D based on a new patented pharmacological target of the pancreatic beta cell, a new protein involved in insulin secretion, cell protection against oxidative stress and apoptosis.</p> <p>This protein, a zinc transporter, has strong potential in beta cell protection and functionality, which makes this new approach fit perfectly with the attempt to explore molecular pathways underlying decreased beta cell mass in diabetes mellitus.</p>
Keywords	Beta cell, apoptosis, oxidative stress, diabetes, insulin, zinc
Partners already involved	

Profile of SME / partner sought

Role	<input checked="" type="checkbox"/> technology development <input checked="" type="checkbox"/> research <input type="checkbox"/> training
	<input type="checkbox"/> dissemination <input type="checkbox"/> demonstration <input type="checkbox"/> other _____
Country /region	Europe

Start of partnership Expertise required	<input checked="" type="checkbox"/> start-up phase	<input type="checkbox"/> mid-term	<input type="checkbox"/> end-phase
	Beta cell expertise Functional genomics on both in vivo and in vitro models		

PROJECT idea 2

Development of preventive & therapeutic strategies for Type 1 diabetes with strong SME involvement	Combating diabetes
---	---------------------------

Project type	<input type="checkbox"/> Integrated Project	<input type="checkbox"/> Network of Excellence	<input checked="" type="checkbox"/> STREP	<input type="checkbox"/> Other: _____
Status	<input checked="" type="checkbox"/> planned for submission <input type="checkbox"/> running EU project			
Call references	Call 4 / combating major diseases / Applications-orientated genomic approaches to medical knowledge and technologies / LSH-2005-2.1.1-11			

Topic (according to the workprogramme)	LSH-2005-2.1.1-11 : Development of preventive & therapeutic strategies for Type 1 diabetes with strong SME involvement
---	---

Project description

Project description	<p>Mellitech is a SME dedicated to developing :</p> <ul style="list-style-type: none"> - new drugs for the treatment of type II diabetes - bio-tools to enhance diabetes research, through better beta cell comprehension and manipulation (monoclonal antibody) and an animal model for type I <p>Mellitech is conducting R&D based on a new patented pharmacological target of the pancreatic beta cell, a new protein involved in insulin secretion, cell protection against oxidative stress and apoptosis.</p> <p>Our technology enables developments based on polymorphisms, auto-immunity, stem cell differentiation, preparation and quality control of Langerhans islets.</p>
Keywords	Insulin, zinc, diabetes, pancreas, beta cell, oxidative stress, apoptosis, auto-immunity, polymorphism, langerhans islets, quality control, stem cell, differentiation, murine model
Partners already involved	

Profile of SME / partner sought

Role	<input checked="" type="checkbox"/> technology development	<input checked="" type="checkbox"/> research	<input type="checkbox"/> training
	<input type="checkbox"/> dissemination	<input type="checkbox"/> demonstration	<input type="checkbox"/> other _____
Country /region	Europe		
Start of partnership	<input checked="" type="checkbox"/> start-up phase	<input type="checkbox"/> mid-term	<input type="checkbox"/> end-phase
Expertise required	Animal model Pancreas protection Molecular biology Cellular biology		

CONTACT

Organisation	INSERM	Department	FUNCTIONAL GENOMICS
Contact person	SIMONNEAU	Male/female	M
Address	Hôpital R.DEBRE 48 Bvd Sérurier	Email	simoneau@infobiogen.fr
Postcode	75019	Fax	33140031903
City	Paris	Website	
Country	France		

Are you familiar with the European Framework Programme? YES

PROJECT

Title		Acronym	
Project type	SME STREP		
Status	planned for submission		
Call references			

Priorities' Main Research Area :

Topic (according to the workprogramme)	LSH-2005-2.1.3-6 Neuroscience-oriented new technologies
---	---

Project description

Project description	<p>New technologies for studies of sub-groups of neurons : their applications to mouse models of multifactorial psychiatric diseases</p> <ul style="list-style-type: none"> •Goals •identification of sub-groups of neurons : • differential expression analysis from these identified neurons (control versus transgenic or versus experimentally manipulated : i.e. siRNAs) • proteomics from identified neurons : single cell <p>-> proof of concept : applications to mouse models of multifactorial psychiatric diseases</p>
Keywords	Transgenic mouse; laser microdissection; transcriptome; single cell proteomics
Partners already involved	

Profile of SME / partner sought

Role	<input checked="" type="checkbox"/> technology development	<input type="checkbox"/> research	<input type="checkbox"/> training
-------------	--	-----------------------------------	-----------------------------------

	<input type="checkbox"/> dissemination	<input type="checkbox"/> demonstration	<input type="checkbox"/> other _____
Country /region			
Start of partnership	<input checked="" type="checkbox"/> start-up phase	<input type="checkbox"/> mid-term	<input type="checkbox"/> end-phase
Expertise required	We search for two SME partners : (i) a SME involved in transgenic technology (ii) a SME involved in proteomics (i.e. expertise in antibodies; single cell kinomics)		

Date 2005 05 04

Deadline 2005 12 01

CONTACT

Organisation	CeeD	Department	-
Contact person 1	Mr. Belcourt	Male/female	Male
Contact person 2	Mme Séverine Sigrist		Female
Address	1, boulevard René Leriche	Email	ceedab@aol.com ceed.sigrist@wanadoo.fr
Postcode	67200	Fax	00 33 (0)3 90 20 12 19
City	Strasbourg	Website	-
Country	France		

Are you familiar with the European Framework Programme? YES NO

PROJECT

Title Oral Administration of active principles with therapeutical effect

Acronym to be found

Project type	<input type="checkbox"/> Integrated Project	<input type="checkbox"/> Network of Excellence	<input checked="" type="checkbox"/> STREP	<input type="checkbox"/> Other:
Status	<input checked="" type="checkbox"/> planned for submission <input type="checkbox"/> running EU project			
Call references	Application of knowledge and technologies in the field of genomics and biotechnology for health / Rational and accelerated development of new, safer, more effective drugs including pharmacogenomics approaches			

Topic (according to the workprogramme) LSH-2005-1.2.1-2: New tools to investigate ADME properties of drugs involving a carrier system.

Project description

Project description	<p>Though the oral administration represents the most physiological and comfortable route to give drugs, many active principles fail to pass through the digestive tract where they are denatured or degraded. In addition, their absorption might be limited, not to say prohibited, by the intestinal barrier.</p> <p>Therefore, we have conceived vectors to protect the active principle against the aggressive environment of the stomach and to facilitate its absorption at the intestinal level.</p>
Keywords	Encapsulation, Biopolymers, Diabetes, Vectors, Drugs, Therapy
Partners already involved	ICS-CNRS (FR), Res Centre: Polymers/Biopolymers CeeD (FR), Res Inst: Diabetology/Endocrinology Université Libre de Bruxelles (BE), University: Experimental hormonology Università di Pisa (IT), University: Diabetology CTTM (FR), Res Centre: Chemistry - polymers JMUW (DE), Univeristy: Microsurgery UCL (BE), University: Analyses of surfaces and interfaces

Profile of SME / partner sought

Role	<input type="checkbox"/> technology development	<input checked="" type="checkbox"/> research	<input type="checkbox"/> training
	<input type="checkbox"/> dissemination	<input type="checkbox"/> demonstration	<input type="checkbox"/> other _____
Country /region	All EU countries but France and UK		
Start of partnership	<input checked="" type="checkbox"/> start-up phase	<input type="checkbox"/> mid-term	<input type="checkbox"/> end-phase
Expertise required	<ul style="list-style-type: none"> - Encapsulation - Biopolymers - Polymers synthesis - Transgenic animals 		

CONTACT

Organisation	WatchFrog	Department	
Contact person	Gregory Lemkine	Male/female	M
Address	7 rue Cuvier	Email	lemkine@
Postcode	75005	Fax	+ (0)140793618
City	Paris	Website	www.watch-frog.com
Country	France		

Are you familiar with the European Framework Programme? YES NO

PROJECT

Title				Acronym	
Project type	<input type="checkbox"/> Integrated Project	<input type="checkbox"/> Network of Excellence	<input checked="" type="checkbox"/> STREP	<input type="checkbox"/> Other: _____	
Status	<input checked="" type="checkbox"/> planned for submission		<input type="checkbox"/> running EU project		
Call references					

4th Call / Specific STREP dedicated to SMEs call : targeted topics

- Development of new in vitro tests to replace animal experimentation
- Characterisation and use of animal models for neurological and psychiatric diseases

Project description

Project description	<p>Our main objective is to design and validate amphibian models (xenopus) to simplify and reduce the delay for results in the field of new drug discovery for neurological disease.</p> <p>The new generation of tests offered by WatchFrog is allied to the development of amphibian models in order to replace, reduce or refine (3Rs of animal protection policies) the use of animal models in drug discovery. Its technology allows testing as many options as needed by its very cost-effective approach. Furthermore, the automatization of reading results allows the simplicity and low cost of <i>in vitro</i> tests to be combined with the biological pertinence of <i>in vivo</i> analysis. Basically WatchFrog models will "light up" (through emission of fluorescence) when a biological function is activated.</p> <p>The genetic and physiological proximity between humans and xenopus is particularly well established and recognized for endocrine regulation. Other physiological and pathological fields can also benefit from Wathfrog technology. For these, xenopus is again relevant in that it very rapidly develops a vascular system and a complex central nervous system in the course of its growth.</p>
Keywords	Drug discovery, alternative models, neurological diseases, neurotoxicity
Partners already involved	

Profile of SME / partner sought

Role	<input checked="" type="checkbox"/> technology development	<input checked="" type="checkbox"/> research	<input type="checkbox"/> training
	<input type="checkbox"/> dissemination	<input type="checkbox"/> demonstration	<input type="checkbox"/> other _____
Country /region			
Start of partnership	<input type="checkbox"/> start-up phase	<input checked="" type="checkbox"/> mid-term	<input checked="" type="checkbox"/> end-phase
Expertise required	<p>Specific cooperation with innovative players in the pharmaceutical industry that are focused on developing short term results thus speeding up their drug discovery process.</p> <p>We also propose to collaborate with another research group working on cell culture testing or fish early life stage test. Substances with known activity could be tested in parallel, giving direct comparison between models.</p>		

Date 2005 may 26

Deadline jjjj mm dd

CONTACT

Organisation	Institut de Biologie Structurale	Department	
Contact person	D. Gulino	Male/female	F
Address	41 rue Jules Horowitz	Email	gulino@ibs.fr
Postcode	38027	Fax	04 38 78 92 04
City	Grenoble	Website	http://www.ibs.fr/content/ibs/home/
Country	France		

Are you familiar with the European Framework Programme? YES NO

PROJECT

Title	Acronym VE cad
--------------	-----------------------

Project type	<input type="checkbox"/> Integrated Project	<input type="checkbox"/> Network of Excellence	<input checked="" type="checkbox"/> STREP (SME STREP)	<input type="checkbox"/> Other: _____
Status	<input type="checkbox"/> planned for submission <input type="checkbox"/> running EU project			
Call references	LSH-2005-2.1.1-10			

Topic (according to the workprogramme)	Combating cardiovascular disease, diabetes and rare diseases / Research on cardiovascular disease with strong SME involvement
---	---

Project description

Project description	<p>Project : VE cadherin and cardiac diseases</p> <p>The project is based on recently published research results dealing with VE cadherin, an adhesive receptor specifically expressed at the surface of endothelium. By elaborating homophilic interactions which allow connexions between neighbouring endothelial cells, VE cadherin is involved in the maintenance of endothelium integrity. This receptor is also involved in several signalling pathways which can regulate the endothelium permeability.</p> <p>We demonstrated that, following their adhesion on endothelium, neutrophils expressed at their surface two proteases, elastase and cathepsin D. These surface-bound proteases are able to cleave the extracellular part of VE cadherin at the sites of leukocyte adhesion. The subsequent confined disruption of VE cadherin-mediated homophilic interactions could induce formation of gaps between endothelial cells through which neutrophils could migrate from the vasculature into the underlying tissues. This correlates with the fact that blockage of the activity of surface-linked proteases inhibit the transmigration of neutrophils in a cellular model using transwell units.</p> <p>We want to develop molecules able to block VE cadherin cleavage by elastase and cathepsin G to generate drug-candidates able to inhibit the transmigration of leukocytes. For this, we developed an ELISA to visualize</p>
----------------------------	--

	<p>the cleavage occurring on the extracellular part of VE cadherin. This ELISA could be used for the high-throughput screening of a chemical library.</p> <p>Recently, it was demonstrated that VE cadherin can interact with fibrin and not fibrinogen. In 2005, it was established that the inhibition of this interaction by fibrinogen-derived peptides block the transmigration of leukocytes in <i>in vitro</i> transmigration model and in <i>in vivo</i> in an acute and chronic rat model of myocardial ischemia-reperfusion.</p> <p>Fragments of VE cadherin or anti-VE cadherin antibodies can be used instead of fibrinogen-derived peptides to inhibit transmigration of leukocytes in vitro and in vivo. They can represent potential candidates for myocardial reperfusion therapy in humans.</p>	
Keywords	Endothelium, VE cadherin, adhesion, maladies cardio-vasculaire	
Partners already involved	Laboratoire du Développement et du Vieillissement de l'Endothélium Inserm EMI 02-19 Institut de Biologie Structurale (CNRS/ CEA/ Univ J. Fourier)	
Project budget (for the running projects)		Budget reserved for SMEs

Profile of SME / partner sought

Role	<input checked="" type="checkbox"/> technology development	<input type="checkbox"/> research	<input type="checkbox"/> training
	<input type="checkbox"/> dissemination	<input type="checkbox"/> demonstration	<input type="checkbox"/> other _____
Country /region			
Start of partnership	<input checked="" type="checkbox"/> start-up phase	<input type="checkbox"/> mid-term	<input type="checkbox"/> end-phase
Expertise required	<ul style="list-style-type: none"> - Animal model for cardiac diseases - High-throughput screening of a chemical library 		

Project ideas and SME competencies presented by Euresearch, TP1 and TP5 National Contact Point in Switzerland.

An event, similar to the Paris 31st of May event, will be organised in Geneva on the 29th of June by Euresearch in order to promote partnership building and SME participation in the last TP1 and TP5 FP6 calls.

CONTACT

Organisation	Covalys Biosciences AG	Department	
Contact person	<i>Dr. Andreas Brecht</i>	Male/female	<i>M</i>
Address	<i>Benkenstrasse 254</i>	Email	<i>andreas.brecht@covalys.com</i>
Postcode	<i>4108</i>	Fax	<i>+41 61 725 20 55 / Tel: +41 61 725 20 52</i>
City	<i>Witterswil</i>	Website	<i>www.covalys.com</i>
Country	<i>Switzerland</i>		

Are you familiar with the European Framework Programme? YES NO

PROJECT idea

Title				Acronym			
Project type	<input type="checkbox"/> Integrated Project	<input type="checkbox"/> Network of Excellence	<input type="checkbox"/> STREP	<input type="checkbox"/> Other:			
Status	<input type="checkbox"/> planned for submission		<input type="checkbox"/> running EU project				
Call references	<i>See project description</i>						

4th Call / Specific STREP dedicated to SMEs call : topics targeted

See project description

Project description

Project description

Covalys focus are proprietary technologies for protein labeling, protein immobilization and protein purification
 Initial work is focused on the SNAP-tag, a protein tag that covalently binds a wide range of fluorescent and affinity labels
 Covalys holds patent applications and exclusive licenses for a range of protein labeling technologies (in cells and in vitro), as well as protein purification technology

- **Gene expression and proteomics**
 LSH-2005-1.1.1-1: A systems approach to understanding the regulation of gene transcription *INTEGRATED PROJECT*

Objectives:
 to enable researchers to better decipher the functions of genes and gene products as well as to define the complex regulatory networks that control fundamental biological processes.

Interest by Covalys:
 Covalys is interested to provide, to apply, and to extend its protein labeling technologies for the systematic study of gene transcription regulation. Activities in simple eukaryotes (yeast) or in more complex organisms are of interest. One important application would be the use of intracellular FRET assays based on Covalys labeling technology

- **Structural genomics**
 LSH-2005-1.1.2-1: Structural genomics interdisciplinary initiative *INTEGRATED PROJECT*

Objectives:

to enable researchers to determine, more effectively and at a higher rate than is currently feasible, the 3-D structure of proteins and other macromolecules which is important for elucidating protein function and is essential for drug design.

Interest by Covalys:

One important requirement for 2D and 3D crystallization of proteins is the straightforward and simple purification of proteins. Covalys is working on protein-tags and as well on efficient and selective chemical technologies to remove a protein from a surface. Both techniques can be used to optimize the availability of proteins for subsequent crystallization.

- **Multidisciplinary functional genomics approaches to basic biological processes**

LSH-2005-1.1.0-3: Proposals concerned with the development of tools and technologies for functional genomics (proteomics, gene expression, structural genomics, comparative genomics, population genetics, bioinformatics etc) will be eligible. Furthermore, research focusing on multidisciplinary fundamental genomics approaches to study basic biological processes will be considered

STREP dedicated to SMEs

Objectives:

to enable researchers to study fundamental biological processes by integrating the above innovative approaches.

Interest by Covalys:

Covalys technology allows to study the fate of a target protein in vitro, in cells, or even inside small living animals. One important potential is to establish protein interaction assays inside cells, even for medium or weak interactions. Covalys would be interested to participate in a project targeting the intracellular study of protein interactions making use of Covalys' specific protein tagging technology.

- **Development of new diagnostics**

LSH-2005-1.2.2-3: Nanoparticles-based diagnostics STREP

Objectives:

New diagnostic tests and development of new tools and non-invasive methods for early diagnosis, monitoring of disease progression and interpretation of in-vivo data so as to increase the possibilities and effectiveness of the existing therapies.

Interest by Covalys:

Covalys technology allows the effective and biocompatible immobilization of proteins to modified surfaces, e.g. to nanoparticles. Covalys would be interested to participate in a project on nanoparticle based diagnostics, making use of its proprietary immobilization technology. Covalys would be glad to contribute its technology and to develop the technology further for improved yields, reduced non-specific binding, etc.

- **Studying the brain and combating diseases of the nervous system**

LSH-2005-2.1.3-1: Neuroimaging: "Bridging genetics and neural function Integrated Project

Objectives:

use genome information to understand better the functioning and dysfunctioning of the brain, in order to gain new insight into mental processes, to combat neurological disorders and diseases, and to improve brain repair.

Interest by Covalys:

Covalys technology allows to express a protein tag on the surface of certain cells within an organism and subsequently to label this protein tag covalently with a label of choice. Of particular interest are fluorescent labels with excitation and

	emission in the range from 650nm to 950nm which allow the use of imaging technologies even in small living mammalian animals. Covalys would be interested to develop and to optimize such labels for use in 'in vivo' studies in the neural systems of such animals.
Keywords	
Partners already involved	

Profile of SME / partner sought

Role	<input type="checkbox"/> technology development	<input type="checkbox"/> research	<input type="checkbox"/> training
	<input type="checkbox"/> dissemination	<input type="checkbox"/> demonstration	<input type="checkbox"/> other _____
Country /region			
Start of partnership	<input type="checkbox"/> start-up phase	<input type="checkbox"/> mid-term	<input type="checkbox"/> end-phase
Expertise required			

CONTACT

Organisation	ADDEX Pharmaceuticals SA	Department	
Contact person	Dr. Vincent Mutel	Male/female	M
Address	12, Chemin des Aulx	Email	Vincent.mutel@addexpharma.com
Postcode	1228	Fax	Tel: +41228841555 Fax: +41228841556
City	Plan les Ouates	Website	www.addexpharma.com
Country	Switzerland		

Are you familiar with the European Framework Programme? YES NO

PROJECT idea

Title		Acronym	
Project type	<input type="checkbox"/> Integrated Project	<input type="checkbox"/> Network of Excellence	<input type="checkbox"/> STREP
Status	<input type="checkbox"/> planned for submission	<input type="checkbox"/> running EU project	<input type="checkbox"/> Other:
Call references	See project description		

4th Call / Specific STREP dedicated to SMEs call : topics targeted
See project description

Project description

Project description	<p>Develops therapeutics for the treatment of Central Nervous System (CNS) disorders</p> <p>Focus on novel targets and has proprietary compounds in preclinical and clinical development for the treatment of large CNS indications including Alzheimer's disease, schizophrenia, anxiety, depression, pain and Parkinson's disease</p> <p>Currently developing a new class of drugs that exert a modulatory activity on specific CNS targets. These modulators offer greater selectivity, superior drug-ability and in-built safety.</p> <ul style="list-style-type: none"> ▪ Rational and accelerated development of new, safer, more effective drugs including pharmacogenomics approaches <p>LSH-2005-1.2.1-1: Marker profiling as a new tool for predictive toxicology Integrated Project (IP)</p> <ul style="list-style-type: none"> ▪ Studying the brain and combating diseases of the nervous system <p>LSH-2005-2.1.3-7: Characterisation and use of animal models for neurological and psychiatric diseases STREP dedicated to SMEs LSH-2005-2.1.3-8: Early markers and new targets for neurodegenerative diseases STREP dedicated to SMEs</p> <p>Term commitment: medium (1 – 3 years)</p>
----------------------------	---

Keywords

Partners already involved

Expected result: Develop further specific know-how and techniques for the allosteric modulation

Profile of SME / partner sought

Role

<input type="checkbox"/> technology development	<input type="checkbox"/> research	<input type="checkbox"/> training
<input type="checkbox"/> dissemination	<input type="checkbox"/> demonstration	<input type="checkbox"/> other _____

Country /region

--

Start of partnership

<input type="checkbox"/> start-up phase	<input type="checkbox"/> mid-term	<input type="checkbox"/> end-phase
---	-----------------------------------	------------------------------------

Expertise required

--

CONTACT

Organisation	INPHENO AG	Department	
Contact person	Dr. Francois Hamy	Male/female	M
Address	Vesalgasse	Email	francois.hamy@inpheno.com
Postcode	1 4002	Fax	Tel: +41 61 284 8150 / Fax: +41 61 284 8154
City	Basel	Website	www.inpheno.com
Country	Switzerland		

Are you familiar with the European Framework Programme? YES NO

PROJECT idea

Title		Acronym	
Project type	<input type="checkbox"/> Integrated Project	<input type="checkbox"/> Network of Excellence	<input type="checkbox"/> STREP
Status	<input type="checkbox"/> planned for submission	<input type="checkbox"/> running EU project	<input type="checkbox"/> Other:
Call references	See project description		

4th Call / Specific STREP dedicated to SMEs call : topics targeted
See project description

Project description

Project description	<p>Molecular diagnostic through genotypic and Phenotypic testing of resistance to therapies in the field of Virology (specialized in HIV) and Oncology (specialized in Leukemia and GIST) Molecular biology, Cellular Biology, Virology Assay development Phenotypic cellular assays Drug screening Drug profiling Patient selection Phase III and IV accompaniment</p> <ul style="list-style-type: none"> ▪ Development of new diagnostics LSH-2005-1.2.2-4: Development of new diagnostics STREP dedicated to SMEs Innovative research in post-genomics, which has high potential for application LSH-2005-1.2.5-3: Use of cell lines to define new bioassays for the identification of therapeutic bio-molecules (especially orientated towards small and medium sized companies) STREP LSH-2005-1.2.5-4: Innovative research in post-genomics, which has high potential for application STREP dedicated to SMEs. LSH-2005-1.2.5-2: Post-genomic approaches exploiting aquatic molecular biodiversity for biomedical applications INTEGRATED PROJECT ▪ Combating resistance to antibiotics and other drugs LSH-2005-2.1.2-4: Development of new diagnostic tests for the management and control of antimicrobial resistance STREP dedicated to SMEs
----------------------------	--

<p>Keywords</p> <p>Partners already involved</p>	<ul style="list-style-type: none"> ▪ Combating Cancer LSH-2005-2.2.0-1: Broadening the knowledge base on the molecular mechanisms underlying chemotherapy resistance, therapeutic escape, efficacy and toxicity INTEGRATED PROJECT ▪ Developing new promising candidate vaccines and therapies LSH-2005-2.3.0-1: HIV/AIDS Therapeutic Clinical trials network NETWORK OF EXCELLENCE LSH-2005-2.3.0-4: New approaches for research into host/vector-pathogen interaction for HIV/AIDS, malaria and tuberculosis STREP LSH-2005-2.3.0-10: SME-driven innovations for poverty related diseases STREP dedicated to SMEs <p>Term commitment: medium (1 – 3 years) Expected result: Scientific collaborations, publications, Funding of research fellowships, Development of new systems</p>

Profile of SME / partner sought

Role	<input type="checkbox"/> technology development	<input type="checkbox"/> research	<input type="checkbox"/> training
	<input type="checkbox"/> dissemination	<input type="checkbox"/> demonstration	<input type="checkbox"/> other _____
Country /region			
Start of partnership	<input type="checkbox"/> start-up phase	<input type="checkbox"/> mid-term	<input type="checkbox"/> end-phase
Expertise required			

CONTACT

Organisation	FACHHOCHSCHULE BEIDER BASEL (FHBB)	Department	
Contact person	Eric Kübler & Daniel Gygax	Male/female	
Address	Abteilung Chemie Gründenstrasse 40	Email	eric.kuebler@fhbb.ch ; daniel.gygax@fhbb.ch
Postcode	4132	Fax	Tel: +41 61 467 45 94
City	Muttenz	Website	www.fhbb.ch
Country	Switzerland		

Organisation	MYOVEC INC.	Department	
Contact person	DR. DENIS BRON	Male/female	
Address	MÜHLEFELD 12	Email	denis.bron@myovec.com
Postcode	5016	Fax	Tel: + 41 78 891 58 68
City	Obererlinsbach	Website	www.myovec.com
Country	Switzerland		

Are you familiar with the European Framework Programme? YES NO

PROJECT idea

Title	Acronym		
Project type	<input checked="" type="checkbox"/> Integrated Project	<input type="checkbox"/> Network of Excellence	<input type="checkbox"/> STREP
Status	<input type="checkbox"/> planned for submission	<input type="checkbox"/> running EU project	
Call references	LSH-2005-1.2.2-1: Development of new diagnostics / High throughput molecular diagnostics for hereditary diseases		

Project description

Project description	<p>Our aim is to identify biomarkers from the proteom and / or from a sub-proteom of the blood serum in order to diagnose hereditary muscle diseases at the earliest clinical stage (first symptoms). In parallel, we currently establish a system for efficient mutation detection in any of the many genes involved in muscle diseases. With the supportive results of the genomics approach, the analysis of the blood serum proteom will lead to a fast, specific and sensitive diagnostic tool.</p> <p>In addition, the comparison of genomic and proteomic data might lead to the identification of disease pathways.</p> <p>The project should lead to the development of advanced tools by incorporation of genomics, <u>proteomics</u> and metabolomics in combination with advanced read-out technology. Deliverables must be the development of high throughput, sensitive, reliable and especially cost available genetic tests. The project must address</p>
---------------------	--

Keywords	quality assurance issues and should offer opportunities for industrial exploitation and SMEs. Consideration may be given to ethical issues related to the diagnosis of hereditary diseases.
Partners already involved	

Profile of SME / partner sought

Role	<input type="checkbox"/> technology development	<input type="checkbox"/> research	<input type="checkbox"/> training
	<input type="checkbox"/> dissemination	<input type="checkbox"/> demonstration	<input type="checkbox"/> other _____
Country /region			
Start of partnership	<input type="checkbox"/> start-up phase	<input type="checkbox"/> mid-term	<input type="checkbox"/> end-phase
Expertise required			

CONTACT

Organisation	Plirosoft GmbH	Department	
Contact person	Dr. Epaminondas Kapetanios	Male/female	
Address	Technoparkstrasse	Email	kapetanios@plirosoft.ethz.ch
Postcode	1 8005	Fax	Tel: +41-01 445 1297
City	Zurich	Website	www.plirosoft.ethz.ch
Country	Switzerland		

Are you familiar with the European Framework Programme? YES NO

PROJECT idea

Title		Acronym	
Project type	<input type="checkbox"/> Integrated Project	<input type="checkbox"/> Network of Excellence	<input type="checkbox"/> STREP
Status	<input type="checkbox"/> planned for submission	<input type="checkbox"/> running EU project	<input type="checkbox"/> Other:
Call references	See project description		

Project description

Project description	<p>Specialized in the area of semantic technologies and solutions (ICT) provide solutions to a wide range of problems of today's business and science IT based working environments with an excel on:</p> <ul style="list-style-type: none"> - Semantic Date Integration o Heterogeneous Data Sources - Creation of virtual Data Warehouses - Realization of Metadata repositories and Middleware for third party Integration Solutions - Realization of collaborative Ontology Engineering and sharing environments - Realization of Semantic Querying and Search Engines for large scientif. or technical repositories <p>The company aims at becoming one of the major players in the area of semantic technologies and, therefore, contributes to the realization of knowledge based information societies for social as well as for business environments</p> <ul style="list-style-type: none"> ▪ Developing new promising candidate vaccines and therapies LSH-2005-2.3.0-1: HIV/AIDS Therapeutic Clinical trials network NETWORK OF EXCELLENCE LSH-2005-2.3.0-2: HIV/AIDS Vaccines/Microbicides Network NETWORK OF EXCELLENCE having a considerable experience with data and metadata handling for clinical trials ▪ Structural genomics LSH-2005-1.1.2-1: Structural genomics interdisciplinary initiative
----------------------------	---

Keywords Partners already involved	INTEGRATED PROJECT ▪ Comparative genomics and population genetics LSH-2005-1.1.3-3: Population cohorts for molecular epidemiological studies in European populations INTEGRATED PROJECT given our experience in dealing with data and knowledge structures as well as their representation

Profile of SME / partner sought

Role	<input type="checkbox"/> technology development	<input type="checkbox"/> research	<input type="checkbox"/> training
	<input type="checkbox"/> dissemination	<input type="checkbox"/> demonstration	<input type="checkbox"/> other _____
Country /region			
Start of partnership	<input type="checkbox"/> start-up phase	<input type="checkbox"/> mid-term	<input type="checkbox"/> end-phase
Expertise required			

CONTACT

Organisation	TheraStrat AG	Department	
Contact person	Dr. Hubert Hug	Male/female	
Address	Gewerbestrasse 25	Email	hubert.hug@therastrat.com
Postcode	4123	Fax	Tel: +41-61-48550-17 Fax: +41-61-48550-29
City	Allschwil	Website	www.therastrat.com
Country	Switzerland		

Are you familiar with the European Framework Programme? YES NO

PROJECT idea

Title				Acronym	
Project type	<input type="checkbox"/> Integrated Project	<input type="checkbox"/> Network of Excellence	<input type="checkbox"/> STREP	<input type="checkbox"/> Other: _____	
Status	<input type="checkbox"/> planned for submission		<input type="checkbox"/> running EU project		
Call references	See project description				

Project description

Project description	<p>TheraStrat's primary mission is to develop sets of theragenomic tools, which in concert allow providing personalized drug safety to single individuals (i.e. patients). TheraStrat develops sophisticated postgenomic database and knowledge management and discovery systems on the molecular and genetic basis of serious ADRs (SafeBase™) with a focus on those factors critical for the prediction of serious ADRs towards a given drug in individual patients. TheraStrat develops sets of structural and genetic fingerprints (SafePat™) predictive of the susceptibility of human individuals for the development of serious ADRs towards a given drug. TheraStrat develops expertise and consulting services on the use of theragenomics in drug development and clinical practice, also including postgenomic database design and implementation of related bioinformatic concepts and solutions (AdeCon™).</p> <ul style="list-style-type: none"> ▪ Rational and accelerated development of new, safer, more effective drugs including pharmacogenomics approaches <p>LSH-2005-1.2-1-3: Rational and accelerated development of new, safer, more effective drugs including pharmacogenomics approaches STREP dedicated to SMEs</p> <p>LSH-2005-1.2.1-1: Marker profiling as a new tool for predictive toxicology INTEGRATED PROJECT.</p> <p>Term commitment: long (> 3 years)</p> <p>Expected result: Development of new tools for predictive toxicology; Methods and Systems for improved medical knowledge discovery and understanding through integration of biomedical information.</p>
----------------------------	--

Thematic Priority 5
« Food quality and Safety »

CLASSIFICATION OF PROJECT IDEAS AND SME COMPETENCIES

1. Total food chain
 2. Epidemiology of food-related diseases and allergies
 3. Impact of food on health
 - CRITT Poitou Charentes – STREP (*presented in the session*) p.36
 4. Traceability processes along the production chain
 - ADRIA ACTIA – IP (*presented in the session*)p.38
 - ACTIA – IP (*presented in the session*)p.40
 - ECCLOR Europe sas – IP (*presented in the session*)p.42
 5. Methods of analysis, detection and control
 6. Safer and environmentally friendly production methods and technologies and healthier food stuffs
 7. Impact of animal feed on human health
 8. Environmental health risks
 - WATCHFROG – STREPp.34
- OTHER Cooperation opportunity in Food Quality and Safety :**
- INRA – CRAFT (*presented in the session*)p.45

CONTACT

Organisation	WatchFrog	Department	
Contact person	Gregory Lemkine	Male/female	M
Address	7 rue Cuvier	Email	lemkine@
Postcode	75005	Fax	+ (0)140793618
City	Paris	Website	www.watch-frog.com
Country	France		

PROJECT

ACRONYM :

Project Type : Integrated Project Network of Excellence Other : STREP..

Status Planned for submission Running EU project

Refers to call 1st call 2nd call 3rd call 4th call

Main research area : Environmental health risks

Topic (according to the work programme)

Investigation of potential health impacts of long-term exposure to disinfection by-products in drinking water (STREP)

Project description

Title of the project	
Project description	<p>Our main objective is to design and validate amphibian (xenopus) models that will reflect physio-pathological effects of water pollutants on three main human health axis: cancer, neuro-developmental impairments and endocrine disruption. Application of REACH european guidelines will require appropriate models for testing over 80.000 chemicals, in particular regarding their endocrine disrupting effects that could induce cancer or neuro-developmental impairments.</p> <p>The new generation of tests offered by WatchFrog is allied to the development of amphibian models in order to replace, reduce or refine (3Rs of animal protection policies) the use of animal models. Basically, WatchFrog models will “light up” (through emission of fluorescence) when a biological function is activated.</p> <p>The genetic and physiological proximity between humans and xenopus is particularly well established and recognized for endocrine regulation. Other physiological and pathological fields can also benefit from Wathfrog technology. For these, xenopus is again relevant in that it very rapidly develops a vascular system and a complex central nervous system in the course of its growth.</p>
Keywords	Water, Neurotoxicity, alternative models
Partners involved	
Project budget	Reserved for SMEs

Search profile / partner sought

Role Technology development Research Training
 Dissemination Demonstration Other:

Country / region

Start of partnership Start up phase Mid-term End phase

Expertise required	Academic or SME specialized in chemical analysis of water We also propose to collaborate with another research group working on cell culture testing or fish early life stage test. Substances with known activity could be tested in parallel, giving direct comparison between models.
Keywords specifying the expertise	<input type="text"/>

Date : 2005 May 24

Deadline : 2005 Sept 30

CONTACT

Organisation	CRITT Poitou Charentes	Department	
Contact person	Philippe Boiron and Laurent Vedrenne	Male/female	M
Address	175, rue de Coureilles	Telephone	+33 5 46 44 84 75
Postcode	17042	E-mail	p.boiron@crittiaa.com ; l.vedrenne@crittiaa.com
City	La Rochelle Cedex 1	Fax	+33 5 46 44 84 76
Country	France	Website	www.crittiaa.com

PROJECT

ACRONYM : Not defined

Project Type : Integrated Project Network of Excellence Other :STREP

Status Planned for submission Running EU project

Refers to call 1st call 2nd call 3rd call 4th call

Main research area : Impact of food on health

Topic (according to the work programme) T5.4.3.3 Optimising food processing for nutritional and environmental quality

Project description

Title of the project	Not defined		
Project description	-following different nutriments during process units -optimizing process with respect to establishment of a compromise including different parameters (environment, organoleptic quality, nutrition, health...) -technology transfer to industry -recommandations to companies		
Keywords	<i>Nutritional quality, lipids and fats, food processing, minimal processing, environment</i>		
Partners involved	Only French research institutes		
Project budget	Not defined	Reserved for SMEs	

Search profile / partner sought

Role Technology development Research Training
 Dissemination Demonstration Other:

Country / region

Start of partnership Start up phase Mid-term End phase

Expertise required

Keywords specifying the expertise

Date : 2005 May 24

Deadline : 2005 Sept 30

CONTACT

Organisation	ADRIA - ACTIA	Department	Microbiology
Contact person	Danièle Sohier - ADRIA	Male/female	F
Address	Z.A. Creac'h Gwen	Telephone	+33 2 98 10 18 18
Postcode	29196	E-mail	daniele.sohier@adria.tm.fr
City	QUIMPER	Fax	+33 2 98 10 18 99
Country	Cedex	Website	adria@adria.tm.fr

PROJECT

ACRONYM : SMITHII

Project Type Integrated Project Network of Excellence Other :

Status Planned for submission Running EU project

Refers to call 1st call 2nd call 3rd call 4th call

Main research area : Traceability processes along the production chain

Topic (according to the work programme) T5.4.4.1 Origin and development of unintended micro-organisms in the food and feed chains.

Project description

Title of the project	Sporeformer Microflora : Identification, Toxicity, Heat treatment during Industrial process and Impact on selection	
Project description	Sporeformers bacillus, including species able to produce highly heat-resistant spores (HRS), have been and are still responsible of contaminations in food industry. Novel species are described, suggesting adaptation to heat treatments applied during food processing, such as Bacillus smithii!... Thus, providing rapid and specific new analysis tools represent the first challenge to ensure food safety and quality during process and products self-lives, by optimising raw material production and orientation, by improving formulations and process...and to dread the effectiveness of a real selective pressure!	
Keywords	<i>Molecular species identification and strains fingerprinting, toxin synthesis quantification, minimal processing, products self-lives, predictive microbiology, risk analysis.</i>	
Partners involved	Only research institutes from France, Hungary, Italy and United Kingdom.	
Project budget	Not defined	Reserved for SMEs

Search profile / partner sought

Role Technology development Research Training
 Dissemination Demonstration Other:

Country / region

Start of partnership Start up phase Mid-term End phase

Expertise required	<ul style="list-style-type: none"> -SMEs and research centers in food diagnostic in order to develop toxin synthesis quantification and strains fingerprinting methods -Research and consulting organisation in risk analysis and minimal thermal processing -Expert in bio-terrorism -Research partner in genomic evolution -Veterinary research organism -Food factories interested in the validation steps of the analysis tools
Keywords specifying the expertise	<p><i>Molecular species identification and strains fingerprinting, toxin synthesis quantification, minimal processing, products self-lives, predictive microbiology, risk analysis.</i></p>

Date : 2005 May 24

Deadline : 2005 Sept 30

CONTACT

Organisation	ACTIA	Department	
Contact person	Christophe Cotillon	Male/female	M
Address	16, rue Claude Bernard	Telephone	+33 1 44 08 86 20
Postcode	F-75231	E-mail	c.cotillon@actia.asso.fr
City	Paris Cedex 05	Fax	+33 1 44 08 86 21
Country	FRANCE	Website	www.actia.asso.fr

PROJECT

ACRONYM : **FOOD INDUS TRACE**

Project Type : Integrated Project Network of Excellence Other :

Status : Planned for submission Running EU project

Refers to call : 1st call 2nd call 3rd call 4th call

Main research area : Traceability processes along the production chain

Topic (according to the work programme) : T5.4.4.2 Emerging technologies for food/feed traceability including monitoring the manufacturing and handling practices in the total chain

Project description

Title of the project	Emerging technology for food industry traceability	
Project description	<p>upscaling of research results 3 technological sub projects: 1) Product identification technology 2) Genetic analysis technology (genetic constitution AND contamination) 3) Software technology for traceability system integration 2 major horizontal sub-projects: 1) Technology watch & cost benefit analysis 2) Scaling up & demonstration</p>	
Keywords	<i>Traceability, technologies, software</i>	
Partners involved	4 Core members <u>ACTIA</u> (+ ACTA & ACTIA informatique), <u>Fraunhofer IPA</u> , <u>Danish Technological Institute</u> and <u>FIBL</u> Already 25 expressions of interest including 7 SMEs	
Project budget	Not defined	Reserved for SMEs

Search profile / partner sought

Role Technology development Research Training
 Dissemination Demonstration Other:

Country / region

Start of partnership Start up phase Mid-term End phase

Expertise required	industrial partners (SMEs) for a) Technology transfer in the 3 technological areas b) Demonstration along food supply chain (organic product, wine/meat?)
Keywords specifying the expertise	<i>Traceability, technologies, software</i>

Date : 2005 05 26

Deadline : 2005 09 07

CONTACT

Organisation	ECCLOR Europe sas	Department	Direction
Contact person	VERHEECKE Eric-julien	Male/female	Male
Address	35 Villa CURIAL	Telephone	(00 33 – 0) 6 03 97 32 65
Postcode	75019	E-mail	myscore@ecclor.com or e.verheecke@ecclor.com
City	PARIS	Fax	03 26 07 75 19
Country	France	Website	www.ecclor.com

PROJECT

ACRONYM : MycoScore

Project Type Integrated Project Network of Excellence Other :

Status Planned for submission Running EU project

Refers to call 1st call 2nd call 3rd call 4th call

Main research area : Traceability processes along the production chain

Topic
(according to the
work programme)

T5.4.4.1 Origin and development of unintended micro-organisms in the food and feed chains (IP)

Project description

Title of the project

“MycoScore” - FOOD SAFETY AND CEREAL

Project description :

Research and Development on the health risks linked to the presence of biological contamination in cereals, coffee and grapes

Considering quality matters the Project “MycoScore” will focus on the toxins produced by fungi in the field, during storage and transformation of cereals. Those have harmful consequences on health :

- Over 1ng/ml of contamination in human blood, Ochratoxin A has proved its toxicity : nephrotoxicity, neurotoxicity, hepatotoxicity. It is also cancirogenic and immunosuppressive,
- A human serum dosage over 2ng/ml of Aflatoxin results in a high level of hepatotoxicity and carcinogenicity,
- A dietary ingestion of 0.05µg/kg b.w. per day of Zearalenone has an oestrogenic and a carcinogenic effect.

The traceability of the parameters related to the quality of cereals during the period of growth, storage and the transformation process is the key of the risk management.

The mean is the evolution from a moisture-content / temperature approach to an Aw / temperature control, as referred on the ECCLOR patent and in the EU reports on fungal and mycotoxins risks (reports related to Ochratoxin A EU regulation: (CE) n° 472/2002 of 10/03/2002 and infant food EU regulation: (EU) n°466/2001 of 01/11/2004).

The Research will focus on the mycotoxins production in the cereals as a function of Aw and temperature based on the various fungal risks existing in the different areas.

The objective is to develop and demonstrate the efficiency of the new ECCLOR method for tracing the origin of biological agents contaminating food and animal feed based on the model of their development

Other functions will be added such as germination, dormancy and popping. The target is to ensure that the new method will not perturb other aspects of the quality of the cereals.

The added value of the project is to secure all the supply chain of cereal for transformers. Storage corporations will save in term of product and energy. The EU consumers will beneficiate of a real increase food safety.

This project manages the economical aspects of the new method developed. This include the corporate risks management and insurance, the agro-product or potential label valuation and the organisational impacts at all stages of production chain from the field to the consumer. The economical scheme has to be set up with a Return On Investment (ROI) of 4 years maximum.

A main goal is to create a new technology able to control the Quality of the cereals in the bins and during the transformation process. The spirit of the technology will be conform to the approach developed in the EU regulations and reports.

More than twelve participants have already joined the project. They are working in different areas linked to the cereals storage and transformation such as milling, malting, brewing, popping, infant food and feed production sector.

Today we are looking for worldwide participants in the agro-industrial sectors and also for laboratories, universities and commerce schools and any other sector linked to the problem of the quality of cereals, coffee and grapes, including the mycotoxins aspects.

Keywords	Computational Models, Food contamination, Feed contamination, Crop protection, Sensor, Mycotoxin, E.U. Regulation, DON, Zearalenone, Ochratoxin A		
Partners involved	12 - confidential		
Project budget	15 M€	Reserved for SMEs	5 M€

Search profile / partner sought

Role Technology development Research Training
 Dissemination Demonstration Other:

Country / region

Start of partnership Start up phase Mid-term End phase

Expertise required Partner skills and competencies needed :

Industrials : Agro-industry storing, transporting and/or transforming cereals and co-products for food and feed. Coffee transformers. Grape juice and/or wine producers.
 All industry interested in the mycotoxin prevention / control in their product

Research centers : Laboratories specialized in the quality control of malt, beer, grape juice, wine, floor, starch, protein, food and feed, working on the mycotoxin aspects. Research centers working on: the toxicity of mycotoxins for human and animals; models of development of moulds / mycotoxin produced at field; models of development of moulds / mycotoxins produced during storage. Laboratories specialized in the sensors for mould and/or mycotoxin detection. Commerce school for technology and product positioning and valuation.

Keywords specifying the expertise Mould quantification, Mycotoxin measurement, Creation of model, Mycotoxin toxicity, Cereal transformation.

Project information

Date : 2005 04 22

Deadline : 2005 05 31

CONTACT

Organisation	INRA Lille	Department	
Contact person	Thierry Benezech	Male/female	M
Address	369 rue Jules-Guesde BP 20039	Telephone	33(0)320435412
Postcode	59651	E-mail	Thierry.Benezech@lille.inra.fr
City	Villeneuve d'Ascq cedex	Fax	33(0)320435426
Country	France	Website	

PROJECT

ACRONYM : CoatSensins

Project Type : Integrated Project Network of Excellence Other : CRAFT

Status Planned for submission Running EU project

Refers to call 1st call 2nd call 3rd call 4th call

Main research area	Food Quality and Safety / SME specific measures
Topic	Non relevant
Title of the project	Coated Inserts and Sensors for the Improvement of Mixing and Heat Transfer in Food Processing Considering Fouling and Cleaning behaviours
Project description	<p>The proposed CRAFT research project is twofold: the development of surface coatings to allow both the embedding of sensor and use of removable tube inserts in food process equipments. This will contribute to reliable and hygienic food process transformations and therefore improve food quality and safety.</p> <p>In a second step an experimental program is planned to quantify the benefit of the insert coated surfaces on heat transferring walls. As a real test fluid for heat transfer experiments, chocolate dessert will be used which is a highly viscous, sticky and complex food product. This selection of the most appropriate coated surfaces will be carry out in closed connection with cleaning age tests on the corresponding coated surface. Thereby the deposits on the inserts themselves cannot be neglected for safety food products and it is vital that the proposed coated surface has a long service life. This requires an integrated approach to ascertain that the full process equipment obeying to food processing hygienic requirements. This cleaning age test program will be also the opportunity to test the robustness of the sensor with coated surface and their suitability to provide us pertinent information about the process. The design and optimisation of insert is another important aspect, which will be tackled as well. In particular it will be determine the overall mixing performances of the inserts in order to classify its efficiency. For the investigation of blending, model fluids charged with a coloured tracer will be used.</p>

Keywords	The equipment of the RTD performers allows to study surface topologies and energies at the nano-scale and characterise fouling in terms of the tendency of components to adhere and ease of removal - either as raw foulants, aged deposits or the phases generated by cleaning chemicals (for example, in the dairy industry, alkaline solutions are used to convert proteinaceous soils into soft gels). Linking these nano/micron scale studies to plant performance, however, is a key step, which is achieved by taking a tailored surface for the inserts and using it at the plant scale.	
	Coatings, Inserts, Sensors, Cleanability, Hygienic Engineering	
	<p><u>RTD performers:</u></p> <p>TUBS: Institute for Chemical and Thermal Process Engineering, Technical University of Braunschweig, Prof. Stephan Scholl (Co-ordinator), Dr. Wolfgang Augustin</p> <p>UCAM: Department of Chemical Engineering, University of Cambridge, UK, Dr. Ian Wilson</p> <p>INRA: Institute National de la Recherche Agronomique, F, Dr. Thierry Benezech, Dr. Guillaume Delaplace</p> <p>IST Fraunhofer Institute for Surface Engineering and Thin Films, Dr. Klaus Bewilogua, Ingmar Bialuch</p>	
Project budget		Reserved for SMEs Yes but other companies are required as end users

Search profile

PARTNER SOUGHT

Role Technology development Research Training
 Dissemination Demonstration Other: SME's development.....

Country / region All

Start of partnership Start up phase Mid-term End phase

Expertise required The SME participants searching for improvement of mixing, heat transfer, process monitoring and hygienic engineering will exploit this novel approach. **Final user is the food industry.** Of course other sectors of industry could take advantages of this project. For the coated sensor perspectives are obvious. For insert coated surfaces, one may mention the petroleum industry. Often a limited amount of thermal sensitive additives (< 1%) is added to a viscous basic material. Inserts can achieve the equal distribution of additives and coating with low friction surfaces can reduce the additional pressure drop. So all information about static mixer design and suitability will be welcomed.